Clinical trial
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00079924 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00079924 |
|---|---|
| Title | Effects of Teriparatide in Postmenopausal Women With Osteoporosis |
| Official title | Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | teriparatide, aldrenodate, raloxifene |
| Enrollment | 200 |
| Start date | Nov 1, 2004 |
| Completion | May 1, 2007 |
| First posted | Mar 19, 2004 |
| Last update posted | May 25, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: